Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
CYP19A1	1588	ATROPINE	CHEMBL517712		NCI	2128054
CYP19A1	1588	GENISTEIN	CHEMBL44		NCI	16285913
CYP19A1	1588	HYDROQUINONE	CHEMBL537		NCI	10979580
CYP19A1	1588	PHENYTOIN	CHEMBL16		NCI	9182861
CYP19A1	1588	ATAMESTANE	CHEMBL2105987		TdgClinicalTrial
CYP19A1	1588	AMINOGLUTETHIMIDE	CHEMBL488	inhibitor	TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, NCI, TEND, DrugBank, TTD	17139284, 17016423, 16244789, 11752352, 16332571, 16474421, 17602675, 1590282
CYP19A1	1588	TESTOLACTONE	CHEMBL1571	inhibitor	TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, TEND, DrugBank, TTD	11752352, 9521275, 16766117, 16190763, 11792932
CYP19A1	1588	EXEMESTANE	CHEMBL1200374	inhibitor	DrugBank, GuideToPharmacologyInteractions, TTD, TdgClinicalTrial, TEND, PharmGKB, ChemblInteractions	17020418, 11752352, 19436613, 15814851, 19930708, 19337436, 19156139, 18728707, 20360896
CYP19A1	1588	ANDROSTENEDIONE	CHEMBL274826		NCI	2214767
CYP19A1	1588	LETROZOLE	CHEMBL1444	antagonist, inhibitor	TdgClinicalTrial, TEND, ChemblInteractions, DrugBank, GuideToPharmacologyInteractions, PharmGKB, TTD	14505258, 11752352, 10388095, 15026471
CYP19A1	1588	ANASTROZOLE	CHEMBL1399	inhibitor	TALC, DrugBank, GuideToPharmacologyInteractions, NCI, TEND, TTD, TdgClinicalTrial, PharmGKB, ChemblInteractions	18073378, 17693420, 11752352, 16034487, 19389994, 19794821, 16439860, 19753124, 19470631, 9928668, 9928669
CYP19A1	1588	AZALANSTAT	CHEMBL70611	inhibitor	GuideToPharmacologyInteractions
CYP19A1	1588	FORMESTANE	CHEMBL132530		NCI	6150277
CYP19A1	1588	RUTIN	CHEMBL226335		NCI	11796325
CYP19A1	1588	TESTOSTERONE ENANTHATE	CHEMBL1200335		NCI	8487666
CYP19A1	1588	FADROZOLE	CHEMBL9298	inhibitor	GuideToPharmacologyInteractions
CYP19A1	1588	ASCORBATE	CHEMBL196		NCI	10979580
CYP19A1	1588	IBUPROFEN	CHEMBL521		NCI	15964185
CYP19A1	1588	QUERCETIN	CHEMBL50		NCI	10704911
CYP19A1	1588	KETOCONAZOLE	CHEMBL295698		DrugBank	2004042
CYP19A1	1588	2-METHOXYESTRADIOL	CHEMBL299613		DrugBank	10405348
CYP19A1	1588	ALENDRONIC ACID	CHEMBL870		NCI	14715828
CYP19A1	1588	CAPTOPRIL	CHEMBL1560		NCI	9268216
CYP19A1	1588	ISOPROPYL ALCOHOL	CHEMBL582		NCI	6409434
CYP19A1	1588	LIAROZOLE	CHEMBL389433		NCI	2164659
CYP19A1	1588	AZTREONAM	CHEMBL158		NCI	3566801
CYP19A1	1588	ISOPROTERENOL	CHEMBL434		NCI	6205918
CYP19A1	1588	STAUROSPORINE	CHEMBL388978		NCI	3132919
CYP19A1	1588	LIOTHYRONINE SODIUM	CHEMBL1201119		NCI	3095107

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
CYP19A1	rs4646	AA	anastrozole	efficacy	yes	Median follow up time was 96 months and the association was with disease free survival (DFS). Overall there was no difference in DFS by genotype, however when women were split into the pre-menopausal and post-menopausal group, an association was seen between the AA genotype and DFS, but in opposite directions. The AA genotype was associated with shorter DFS in the post-menopausal women and longer DFS in the pre-menopausal women when compared to the AC and CC genotypes (13.7 months in post-menopausal AA women, and 56.3 months in post-menopausal AC+CC women). Chemotherapy included Cyclophosphamide, Doxorubicin/epirubicin and Fluoracil or Doxorubicin, Cyclophosphamide with/without docetaxel, Cyclophosphamide, Epirubicin or Doxorubicin, Cyclophosphamide followed by Docetaxel or weekly Paclitaxel, CAF (Cyclophosphamide, Doxorubicin/Epirubicin and Fluoracil) followed by Docetaxel or weekly Paclitaxel treatment and others, 10 (2.5%) remained unknown.	Genotype AA is associated with decreased response to anastrozole, letrozole or tamoxifen in women with Breast Neoplasms and Menopause as compared to genotypes AC + CC.	25793413	1444702613
CYP19A1	rs4646	AA	anastrozole	efficacy	yes	Median follow up time was 96 months and the association was with disease free survival (DFS). Overall there was no difference in DFS by genotype, however when women were split into the pre-menopausal and post-menopausal group, an association was seen between the AA genotype and DFS, but in opposite directions. The AA genotype was associated with shorter DFS in the post-menopausal women and longer DFS in the pre-menopausal women when compared to the AC and CC genotypes (87 months in pre-menopausal AA women, and 48.7 months in pre-menopausal AC+CC women). Chemotherapy included Cyclophosphamide, Doxorubicin/epirubicin and Fluoracil or Doxorubicin, Cyclophosphamide with/without docetaxel, Cyclophosphamide, Epirubicin or Doxorubicin, Cyclophosphamide followed by Docetaxel or weekly Paclitaxel, CAF (Cyclophosphamide, Doxorubicin/Epirubicin and Fluoracil) followed by Docetaxel or weekly Paclitaxel treatment and others, 10 (2.5%) remained unknown.	Genotype AA is associated with increased response to anastrozole, letrozole or tamoxifen in women with Breast Neoplasms as compared to genotypes AC + CC.	25793413	1444702623
CYP19A1	rs10046	AA	exemestane	PD	no	Although patients with the AA genotype in combination with the rs4646 CC genotype showed a steeper decrease in serum estradiol concentrations following exemestane treatment, the authors note that this combination of genotypes was associated with a higher baseline level of serum estradiol and that the association between the genotypes and the rate of estradiol decrease lost significance following adjustment for baseline concentrations.	Genotype AA is not associated with response to exemestane in women with Breast Neoplasms as compared to genotypes AG + GG.	30967597	1451101020
CYP19A1	rs700518	CC	Enzyme inhibitors	other	yes	Please note the article studied changes in body composition. CC carriers developed a significant increase in truncal fat mass index (P=0.03) and a significant decrease in fat-free mass index (P=0.01) at 12 months compared to CT/TT carriers.	Genotype CC is associated with response to Enzyme inhibitors in women with Breast Neoplasms as compared to genotypes CC + CT.	26049585	1444880046
CYP19A1	rs1062033	G	hdl cholesterol	other	yes	when taking letrozole and lipid lowering agents (LLA), such as statins. Data are from a sub-analysis of the Exemestane and Letrozole Pharmacogenomics (ELPh) study, where post-menopausal women with early stage breast cancer were randomized to receive exemestane or letrozole. Of the 303 eligible women, 160 were randomized to the letrozole group, 52 of whom were also taking LLA. This SNP was associated with increases in HDL-cholesterol of 6.9 mg/dL (SE 1.5).	Allele G is associated with increased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele C.	26463708	1447677231
CYP19A1	rs749292	A	triglycerides	other	yes	when taking letrozole. Data are from a sub-analysis of the Exemestane and Letrozole Pharmacogenomics (ELPh) study, where post-menopausal women with early stage breast cancer were randomized to receive exemestane or letrozole. Of the 303 eligible women, 160 were randomized to the letrozole group, 52 of whom were also taking LLA. This SNP was associated with decreases in triglycerides ranging from 39.3-20.2 mg/dL using a recessive and additive model, respectively.	Allele A is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele G.	26463708	1447677221
CYP19A1	rs2289105	C	triglycerides	other	yes	when taking letrozole alone or with lipid lowering agents (LLA), such as statins. Data are from a sub-analysis of the Exemestane and Letrozole Pharmacogenomics (ELPh) study, where post-menopausal women with early stage breast cancer were randomized to receive exemestane or letrozole. Of the 303 eligible women, 160 were randomized to the letrozole group, 52 of whom were also taking LLA. This SNP was associated with decreases in triglycerides of 36.45 mg/dL (SE 7.8).	Allele C is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele T.	26463708	1447677286
CYP19A1	rs700518	C	triglycerides	other	yes	when taking letrozole alone or with lipid lowering agents (LLA), such as statins. Data are from a sub-analysis of the Exemestane and Letrozole Pharmacogenomics (ELPh) study, where post-menopausal women with early stage breast cancer were randomized to receive exemestane or letrozole. Of the 303 eligible women, 160 were randomized to the letrozole group, 52 of whom were also taking LLA. This SNP was associated with decreases in triglycerides of 32.3 mg/dL (SE 8.4).	Allele C is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele A.	26463708	1447677364
CYP19A1	rs3759811	C	triglycerides	other	yes	when taking letrozole. Data are from a sub-analysis of the Exemestane and Letrozole Pharmacogenomics (ELPh) study, where post-menopausal women with early stage breast cancer were randomized to receive exemestane or letrozole. Of the 303 eligible women, 160 were randomized to the letrozole group, 52 of whom were also taking LLA. This SNP was associated with decreases in triglycerides of 32.3 mg/dL (SE 9.0).	Allele C is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele T.	26463708	1447677354
CYP19A1	rs4646	A	hdl cholesterol	other	yes	when taking letrozole alone or with lipid lowering agents (LLA), such as statins. Data are from a sub-analysis of the Exemestane and Letrozole Pharmacogenomics (ELPh) study, where post-menopausal women with early stage breast cancer were randomized to receive exemestane or letrozole. Of the 303 eligible women, 160 were randomized to the letrozole group, 52 of whom were also taking LLA. This SNP was associated with decreases in HDL-cholesterol of 4.2 mg/dL (SE 1.16).	Allele A is associated with decreased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele C.	26463708	1447677393
CYP19A1	rs4646	AA + AC	tamoxifen	efficacy	yes	Women were on tamoxifen (n=250) or on unnamed aromatase inhibitors (n=37). Disease free survival was compared at 62.7 weeks and 55.6 weeks follow-up for all women for all women, though different week comparisons were used for each significant association that was found. This association was significant in all women combined and the pre-menopausal subset, but not the post-menopausal subset. The AA genotype was associated with poorer disease free survival in post-menopausal women (p=0.005).	Genotypes AA + AC are associated with increased response to tamoxifen in women with Breast Neoplasms as compared to genotype CC.	26191232	1447987564
CYP19A1	rs4646	AA	tamoxifen	efficacy	yes	Women were on tamoxifen (n=250) or on unnamed aromatase inhibitors (n=37). Disease free survival was compared at 62.7 weeks and 55.6 weeks follow-up for all women for all women, though different week comparisons were used for each significant association that was found. This association was significant in all women combined and the pre-menopausal subset, but had different directions of association in post- and pre-menopausal women.	Genotype AA is associated with decreased response to tamoxifen in women with Breast Neoplasms and Menopause as compared to genotypes AC + CC.	26191232	1449154515
CYP19A1	rs10046	G	hdl cholesterol	other	yes	when taking letrozole and lipid lowering agents (LLA), such as statins. Data are from a sub-analysis of the Exemestane and Letrozole Pharmacogenomics (ELPh) study, where post-menopausal women with early stage breast cancer were randomized to receive exemestane or letrozole. Of the 303 eligible women, 160 were randomized to the letrozole group, 52 of whom were also taking LLA. This SNP was associated with decreases in HDL-cholesterol of 6.2 mg/dL (SE 1.6).	Allele G is associated with decreased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele A.	26463708	1447677275
CYP19A1	rs10046	A	triglycerides	other	yes	when taking letrozole alone or with lipid lowering agents (LLA), such as statins. Data are from a sub-analysis of the Exemestane and Letrozole Pharmacogenomics (ELPh) study, where post-menopausal women with early stage breast cancer were randomized to receive exemestane or letrozole. Of the 303 eligible women, 160 were randomized to the letrozole group, 52 of whom were also taking LLA. This SNP was associated with decreases in triglycerides of 36.4 mg/dL (SE 7.8).	Allele A is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele G.	26463708	1447677307
CYP19A1	rs1008805	G	hdl cholesterol	other	yes	when taking letrozole and lipid lowering agents (LLA), such as statins. Data are from a sub-analysis of the Exemestane and Letrozole Pharmacogenomics (ELPh) study, where post-menopausal women with early stage breast cancer were randomized to receive exemestane or letrozole. Of the 303 eligible women, 160 were randomized to the letrozole group, 52 of whom were also taking LLA. This SNP was associated with decreases in HDL-cholesterol of 6.6 mg/dL (SE 1.7).	Allele G is associated with decreased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele A.	26463708	1447677238
CYP19A1	rs2236722	G	capecitabine	efficacy	not stated	pfSNP identified 2800 SNPS associated with key-words: 5-FU, capecitabine and oxilaplatin and colorectal cancer. Various criteria were used to determine 1536 SNPs to genotype. These SNPs were genotyped in a discovery cohort (N=62) and tested in a validation cohort (N=27). Both cohorts consisted of patients with colorectal cancer metastasis in liver. Five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) were identified as distinguishing the "non-responder" phenotype from the "responder" phenotype when using a logistic regression multivariate model. The AUC for the receiver operating characteristic curve of the 5 SNPs is 0.875. This logistic-based multivariate model is said to be able to identify 39.1% of non-responders.	Allele G is associated with decreased response to capecitabine and fluorouracil in people with Neoplasm Metastasis as compared to allele A.	25372392	1185002481
CYP19A1	rs2289105	T	hdl cholesterol	other	yes	when taking letrozole and lipid lowering agents (LLA), such as statins. Data are from a sub-analysis of the Exemestane and Letrozole Pharmacogenomics (ELPh) study, where post-menopausal women with early stage breast cancer were randomized to receive exemestane or letrozole. Of the 303 eligible women, 160 were randomized to the letrozole group, 52 of whom were also taking LLA. This SNP was associated with decreases in HDL-cholesterol of 6.2 mg/dL (SE 1.6).	Allele T is associated with decreased concentrations of hdl cholesterol in women with Breast Neoplasms and Menopause as compared to allele C.	26463708	1447677450
CYP19A1	rs4775936	C	triglycerides	other	yes	when taking letrozole and lipid lowering agents (LLA), such as statins. Data are from a sub-analysis of the Exemestane and Letrozole Pharmacogenomics (ELPh) study, where post-menopausal women with early stage breast cancer were randomized to receive exemestane or letrozole. Of the 303 eligible women, 160 were randomized to the letrozole group, 52 of whom were also taking LLA. This SNP was associated with decreases in triglycerides of 33.2 mg/dL (SE 8.9).	Allele C is associated with decreased concentrations of triglycerides in women with Breast Neoplasms and Menopause as compared to allele T.	26463708	1447677374
CYP19A1	rs4646	CC	exemestane	PD	no	Although patients with the CC genotype in addition to the rs10046 AA genotype showed a steeper decrease in serum estradiol concentrations following exemestane treatment, the authors note that this combination of genotypes was associated with a higher baseline level of serum estradiol and that the association between the genotypes and the rate of estradiol decrease lost significance following adjustment for baseline concentrations.	Genotype CC is not associated with response to exemestane in women with Breast Neoplasms as compared to genotypes AA + AC.	30967597	1451101060